✉news HealthMedicine first seen 2 h ago, last 50 min ago, peak #2
Insilico Medicine advances AI-designed obesity drug ISM1354
Original: Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease
Insilico Medicine has selected ISM1354, an AI-designed GIPR antagonist, as a preclinical candidate for obesity and related metabolic diseases. The drug was discovered using the company's generative AI platform, adding to a growing pipeline of machine-learning-designed therapeutics. The move places Insilico among the biotech firms racing to develop GIPR-targeting weight-loss treatments alongside established GLP-1 drugs.
Why now: Intense current interest in AI-discovered drugs and new therapeutic targets amid the obesity treatment boom.
Rank over time, top of the chart is #1. 2 snapshots from 2 h ago to 50 min ago.
Evidence
- Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease · Drug Target Review
API: https://socialmediatrends-api.osmike.com/v1/trends/715586